April 3 (Reuters) - Imv Inc IMV.TO :
* NEW PRECLINICAL RESEARCH PRESENTED AT AACR 2019 REVEALS UNIQUE ANTI-CANCER MECHANISM OF ACTION UNDERSCORING IMV'S IMMUNOTHERAPY PROGRAM
* IMV INC - ANALYSES ALSO REVEALED DIFFERENTIATED CHARACTERISTICS OF IMMUNE CELL RESPONSES AND POTENTIAL IMPLICATIONS FOR ENHANCED ANTI-TUMOR EFFICACY
* IMV INC - COMBINING DPX/CPA TREATMENTS WITH A CTLA-4-BLOCKING ANTIBODY INCREASED EFFICACY IN CONTROLLING TUMOR GROWTH IN ANIMAL MODELS